Epaminurad

Epaminurad
Clinical data
Other names	URC102/UR-1102
Identifiers
	IUPAC name (3,5-dibromo-4-hydroxyphenyl)-(2,3-dihydropyrido[4,3-b][1,4]oxazin-4-yl)methanone;
CAS Number	1198153-15-9 ;
PubChem CID	44608229 ;
ChemSpider	35143241 ;
UNII	0YP1ME85GH ;
ChEMBL	ChEMBL4640580 ;
Chemical and physical data
Formula	C14H10Br2N2O3
Molar mass	414.053 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES C1COC2=C(N1C(=O)C3=CC(=C(C(=C3)Br)O)Br)C=NC=C2;
	InChI InChI=InChI=1S/C14H10Br2N2O3/c15-9-5-8(6-10(16)13(9)19)14(20)18-3-4-21-12-1-2-17-7-11(12)18/h1-2,5-7,19H,3-4H2; Key:ZMVGQIIOXCGAFV-UHFFFAOYSA-N;

Last updated December 31, 2025

Epaminurad is an investigational new drug being developed by JW Pharmaceutical for the treatment of gout and hyperuricemia. It is a urate-lowering agent that selectively inhibits the human uric acid transporter 1 (hURAT1), promoting urate excretion.^[1]^[2] As of 2024, epaminurad is undergoing Phase 3 clinical trials to evaluate its efficacy and safety compared to febuxostat in gout patients across multiple Asian countries.^[3]^[1]

References

1 2 "JW Pharmaceutical's Epaminurad Shows Promise for Gout Treatment". Business Korea. 16 January 2024. Retrieved 2024-11-23.
↑ Hou X, Wang Y, Yang Y, Xiao Z (November 2023). "Discovery of Novel Biphenyl Carboxylic Acid Derivatives as Potent URAT1 Inhibitors". Molecules. 28 (21). Basel, Switzerland: 7415. doi: 10.3390/molecules28217415 . PMC 10648204 . PMID 37959834.
↑ Khaja H (9 February 2024). "Emerging Drug Treatments for Gout". Rheumatology Advisor. Retrieved 2024-11-23.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[businesskorea-1] 1 2 "JW Pharmaceutical's Epaminurad Shows Promise for Gout Treatment". Business Korea. 16 January 2024. Retrieved 2024-11-23.

[Hou_2023-2] Hou X, Wang Y, Yang Y, Xiao Z (November 2023). "Discovery of Novel Biphenyl Carboxylic Acid Derivatives as Potent URAT1 Inhibitors". Molecules. 28 (21). Basel, Switzerland: 7415. doi: 10.3390/molecules28217415 . PMC 10648204 . PMID 37959834.

[rheumatologyadvisor-3] Khaja H (9 February 2024). "Emerging Drug Treatments for Gout". Rheumatology Advisor. Retrieved 2024-11-23.

[1]

[2]

[3]